Mario Giuliano

Regione Campania — Italy

Medicine · Health Sciences

45h-index7.4kcitations285works2.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Cells and Metastasis(81), Advanced Breast Cancer Therapies(56), HER2/EGFR in Cancer Research(52), Breast Cancer Treatment Studies(47), Cancer Genomics and Diagnostics(42)

Publications282 total

Serum HDL subfractions are impaired by COVID-19 vaccine in patients with thymic epithelial tumors
Scientific Reports·2026Open Access
HER2-low breast cancer is immune-cold: insights into tumor-infiltrating immune cells and implications for immunotherapy
npj Breast Cancer·2025Open Access
Circulating innate lymphoid cells and IL-18 as potential immune biomarkers in thymic tumors
Frontiers in Immunology·2025Open Access
Association of neoadjuvant chemotherapy dose intensity with pathological complete response and event-free survival in HER2-negative early breast cancer
European Journal of Cancer·2025
Adipocyte‑derived extracellular vesicles sustain mitochondrial metabolism in breast cancer cells: New insights into the cross‑talk between cancer cells and the tumor microenvironment
International Journal of Oncology·2025· 1 citedOpen Access
RSC4All as a machine learning nomogram to predict RSClin™ results in HR+/HER2- node-negative early breast cancer
ESMO Open·2025Open Access
Bridging the Gap: the role of MDM2 inhibition in overcoming treatment resistance in breast cancer
Critical Reviews in Oncology/Hematology·2025· 2 citedOpen Access
Trastuzumab plus lapatinib or chemotherapy in patients with HER2-overexpressed advanced breast cancer: a randomized, phase II trial (GIM12-TYPHER)
The Oncologist·2025Open Access
Abstract P2-09-26: Real world progression free survival in elderly vs. younger HR+/HER2- advanced breast cancer patients treated with first-line endocrine therapy plus CDK4/6i: a sub-analysis of the multicenter, PALMARES-2 study
Clinical Cancer Research·2025
Abstract P2-12-08: Real world progression-free survival after CDK4/6 inhibitors plus endocrine therapy: results from the multicenter SISTER study
Clinical Cancer Research·2025
Abstract P4-05-29: ctDNA and serum thymidine kinase activity as tools to stratify ER+/HER2- metastatic breast cancer patients treated with endocrine therapy and CDK4/6 inhibitors: preliminary results of the TIRESIAS trial
Clinical Cancer Research·2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report
Critical Reviews in Oncology/Hematology·2025· 3 citedOpen Access
Effectiveness comparison of palbociclib, ribociclib and abemaciclib in patients with HR+/HER2- aBC: Updated results from the real-world, Italian study PALMARES-2.
Journal of Clinical Oncology·2025· 1 cited
Evaluating the benefit-risk balance of second-line therapies for HR+/HER2- metastatic breast cancer: A comparative analysis using ASCO VF and ESMO MCBS frameworks.
Journal of Clinical Oncology·2025
Prognostic profiling of hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors beyond progression (BP): A synthetic control arm biomarker analysis.
Journal of Clinical Oncology·2025
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, <i>ERBB2</i>–Negative Metastatic Breast Cancer
JAMA Network Open·2025· 8 citedOpen Access
Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid + letrozole in premenopausal hormone receptor-positive early breast cancer patients
ESMO Open·2025· 4 citedOpen Access
Analysis of Artificial Intelligence Decision-Making in Hormone Receptor-Positive / Human Epidermal Growth Factor 2-Negative Early Breast Cancer within Routine Clinical Practice and Clinical Trial
SSRN Electronic Journal·2025Open Access
Rebound thymic hyperplasia and immune related adverse events: reality or fantasy—a case report
Mediastinum·2024Open Access
AB045. Impact of relative dose intensity of platinum-base chemotherapy as first-line treatment in patients with thymic epithelial tumors
Mediastinum·2024Open Access
page 1 of 15Next →

Frequent Co-authors

Sabino De Placido(29), Grazia Arpino(21), Michelino De Laurentiis(20), Antonio Giordano(14), Massimo Cristofanilli(12), Fabio Puglisi(12), Rachel Schiff(11), Lucia Del Mastro(11), Meghana V. Trivedi(9), Francesco Schettini(8), Carmine De Angelis(8), Valeria Forestieri(7), James M. Reuben(7), Naoto T. Ueno(7), Vicente Valero(7), Mothaffar F. Rimawi(6), Rossella Lauria(6), Ugo De Giorgi(6), Michal Mego(6), Carolina Gutiérrez(5)